News
-
-
PRESS RELEASE
Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Curatis Holding AG reports a 57% increase in business revenues for 2025, reaching CHF 10.8m. Major milestones achieved for corticorelin, including FDA validation and a licensing agreement for Japan -
-
PRESS RELEASE
Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan
Curatis Holding AG and Neupharma announce exclusive agreement to develop and market corticorelin (C-PTBE-01) for peritumoral brain edema treatment in Japan. Agreement involves upfront, milestone payments, and royalties -
-
-
-
PRESS RELEASE
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis Holding AG receives positive outcome confirmation from FDA meeting regarding corticorelin's Phase 3 development plan for patients with PTBE secondary to solid tumor brain metastases -
-
PRESS RELEASE
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis Holding AG reports double-digit revenue growth in H1 2025, signing a significant partnership with Phoenix Labs for C-PTBE-01. Financials show a loss due to increased development expenses for corticorelin
